Proton-transfer-reaction mass spectrometry (PTR-MS) for online monitoring of glucose depletion and cell concentrations in HEK 293 gene therapy processes.

Biomass soft sensor Cell culture PAT Glucose online monitoring HEK 293 cell culture monitoring PTR-MS monitoring rAAV process

Journal

Biotechnology letters
ISSN: 1573-6776
Titre abrégé: Biotechnol Lett
Pays: Netherlands
ID NLM: 8008051

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 04 05 2021
accepted: 01 11 2021
pubmed: 13 11 2021
medline: 17 3 2022
entrez: 12 11 2021
Statut: ppublish

Résumé

The applicability of proton-transfer-reaction mass spectrometry (PTR-MS) as a versatile online monitoring tool to increase consistency and robustness for recombinant adeno-associated virus (rAAV) producing HEK 293 bioprocesses was evaluated. We present a structured workflow to extract process relevant information from PTR-MS data. Reproducibility of volatile organic compound (VOC) measurements was demonstrated with spiking experiments and the process data sets used for applicability evaluation consisted of HEK 293 cell culture triplicates with and without transfection. The developed data workflow enabled the identification of six VOCs, of which two were used to develop a soft sensor providing better real-time estimates than the conventional capacitance sensor. Acetaldehyde, another VOC, provides online process information about glucose depletion that can directly be used for process control purposes. The potential of PTR-MS for HEK 293 cell culture monitoring has been shown. VOC data derived information can be used to develop soft sensors and to directly set up new process control strategies.

Identifiants

pubmed: 34767126
doi: 10.1007/s10529-021-03205-y
pii: 10.1007/s10529-021-03205-y
pmc: PMC8854141
doi:

Substances chimiques

Protons 0
Volatile Organic Compounds 0
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-88

Informations de copyright

© 2021. The Author(s).

Références

Eng Life Sci. 2019 Nov 11;20(1-2):26-35
pubmed: 32625044
Mol Ther. 2016 Feb;24(2):287-297
pubmed: 26437810
Biotechnol Bioeng. 2017 Nov;114(11):2445-2456
pubmed: 28710854
Biotechnol J. 2020 May;15(5):e1900551
pubmed: 32022416
Mol Ther Methods Clin Dev. 2018 Nov 22;13:14-26
pubmed: 30591923
Mol Ther Methods Clin Dev. 2020 Jun 03;18:312-320
pubmed: 32671134
J Virol Methods. 2014 Feb;196:163-73
pubmed: 24239634
Nat Rev Drug Discov. 2021 Mar;20(3):173-174
pubmed: 33495615
Anal Bioanal Chem. 2010 Sep;398(1):137-54
pubmed: 20480150
Trends Biotechnol. 2014 Jun;32(6):329-36
pubmed: 24732022
BioDrugs. 2017 Aug;31(4):317-334
pubmed: 28669112
Appl Environ Microbiol. 2008 Apr;74(7):2179-86
pubmed: 18245241
Biotechnol Bioeng. 2012 Dec;109(12):3059-69
pubmed: 22711525
J Breath Res. 2019 Oct 21;14(1):016002
pubmed: 31430743
Biotechnol Bioeng. 2020 Dec;117(12):3766-3774
pubmed: 32776504
Biotechnol Prog. 2014 Mar-Apr;30(2):496-504
pubmed: 24376199

Auteurs

Benjamin Bayer (B)

Novasign GmbH, Vienna, Austria.
University of Natural Resources and Life Sciences, Vienna, Austria.

Andreas Maccani (A)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Johanna Jahn (J)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Mark Duerkop (M)

Novasign GmbH, Vienna, Austria.
University of Natural Resources and Life Sciences, Vienna, Austria.

Ewald Kapeller (E)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Robert Pletzenauer (R)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Barbara Kraus (B)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.

Gerald Striedner (G)

Novasign GmbH, Vienna, Austria.
University of Natural Resources and Life Sciences, Vienna, Austria.

Juan A Hernandez Bort (JA)

Gene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria. juan.hernandezbort@takeda.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH